icon-folder.gif   Conference Reports for NATAP  
 
 

IDweek

Back grey_arrow_rt.gif
 
 
 
Pharmacokinetics of Cabotegravir in Subjects With Severe Renal Impairment
 
 
  Reported by Jules Levin
IDWeek 2017™; October 4-8, 2017; San Diego, CA
 
R Parasrampuria,1S Ford,2Y Lou,3C Fu,3K Bakshi,4AR Tenorio,5C Trezza,5W Spreen,5P Patel5 1GlaxoSmithKline, Upper Merion, PA; 2GlaxoSmithKline, Research Triangle Park, NC; 3PAREXEL International, Durham, NC; 4GlaxoSmithKline, Collegeville, PA; 5ViiV Healthcare, Research Triangle Park, NC

1026171

1026172

1026173

1026174

Reference: 1. Bowers HF, Culp S, Reese MJ, et al. Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans. Xenobiotica. 2016;46(2):147-162.